191 related articles for article (PubMed ID: 28034073)
1. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years.
Gordon LG; Brynes J; Baade PD; Neale RE; Whiteman DC; Youl PH; Aitken JF; Janda M
Value Health; 2017 Apr; 20(4):593-601. PubMed ID: 28408001
[TBL] [Abstract][Full Text] [Related]
3. Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic.
Watts CG; Cust AE; Menzies SW; Coates E; Mann GJ; Morton RL
JAMA Dermatol; 2015 Feb; 151(2):178-86. PubMed ID: 25389712
[TBL] [Abstract][Full Text] [Related]
4. A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.
Watts CG; Wortley S; Norris S; Menzies SW; Guitera P; Askie L; Mann GJ; Morton RL; Cust AE
Appl Health Econ Health Policy; 2018 Apr; 16(2):235-242. PubMed ID: 29305821
[TBL] [Abstract][Full Text] [Related]
5. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
6. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis.
Mooney MM; Mettlin C; Michalek AM; Petrelli NJ; Kraybill WG
Cancer; 1997 Sep; 80(6):1052-64. PubMed ID: 9305705
[TBL] [Abstract][Full Text] [Related]
7. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.
Tromme I; Legrand C; Devleesschauwer B; Leiter U; Suciu S; Eggermont A; Sacré L; Baurain JF; Thomas L; Beutels P; Speybroeck N
Eur J Cancer; 2016 Nov; 67():38-45. PubMed ID: 27592070
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of reduced follow-up in malignant melanoma.
Hengge UR; Wallerand A; Stutzki A; Kockel N
J Dtsch Dermatol Ges; 2007 Oct; 5(10):898-907. PubMed ID: 17910672
[TBL] [Abstract][Full Text] [Related]
10. Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).
Yan MK; Cust AE; Soyer HP; Janda M; Loewe K; Byars G; Fishburn P; White P; Mahumud RA; Saw RPM; Herschtal A; Fernandez-Penas P; Guitera P; Morton RL; Kelly J; Wolfe R; Mar VJ
Trials; 2023 Mar; 24(1):236. PubMed ID: 36991460
[TBL] [Abstract][Full Text] [Related]
11. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review.
Gordon LG; Rowell D
Eur J Cancer Prev; 2015 Mar; 24(2):141-9. PubMed ID: 25089375
[TBL] [Abstract][Full Text] [Related]
12. Digital Dermoscopy Photographs Outperform Handheld Dermoscopy in Melanoma Diagnosis.
Mintsoulis D; Beecker J
J Cutan Med Surg; 2016 Nov; 20(6):602-605. PubMed ID: 27270098
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial.
Primiero CA; McInerney-Leo AM; Betz-Stablein B; Whiteman DC; Gordon L; Caffery L; Aitken JF; Eakin E; Osborne S; Gray L; Smithers BM; Janda M; Soyer HP; Finnane A
BMJ Open; 2019 Nov; 9(11):e032969. PubMed ID: 31712348
[TBL] [Abstract][Full Text] [Related]
14. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
16. Early Cost-effectiveness Analysis of Electrochemotherapy as a Prospect Treatment Modality for Skin Melanoma.
Pirc E; Federici C; Bošnjak M; Perić B; Reberšek M; Pecchia L; Glumac N; Čemažar M; Snoj M; Serša G; Miklavčič D
Clin Ther; 2020 Aug; 42(8):1535-1548.e2. PubMed ID: 32768246
[TBL] [Abstract][Full Text] [Related]
17. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive tools for the diagnosis of cutaneous melanoma.
Fink C; Haenssle HA
Skin Res Technol; 2017 Aug; 23(3):261-271. PubMed ID: 27878858
[TBL] [Abstract][Full Text] [Related]
19. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study.
Moloney FJ; Guitera P; Coates E; Haass NK; Ho K; Khoury R; O'Connell RL; Raudonikis L; Schmid H; Mann GJ; Menzies SW
JAMA Dermatol; 2014 Aug; 150(8):819-27. PubMed ID: 24964862
[TBL] [Abstract][Full Text] [Related]
20. Mole Mapping for Management of Pigmented Skin Lesions.
Berk-Krauss J; Polsky D; Stein JA
Dermatol Clin; 2017 Oct; 35(4):439-445. PubMed ID: 28886799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
